5 results on '"Georges, Jean"'
Search Results
2. Modifiable risk factors for dementia and dementia risk profiling. A user manual for Brain Health Services—part 2 of 6
- Author
-
Ranson, Janice M., Rittman, Timothy, Hayat, Shabina, Brayne, Carol, Jessen, Frank, Blennow, Kaj, van Duijn, Cornelia, Barkhof, Frederik, Tang, Eugene, Mummery, Catherine J., Stephan, Blossom C. M., Frisoni, Giovanni B., Ribaldi, Federica, Molinuevo, José Luis, Scheltens, Philip, Llewellyn, David J., Abramowicz, Marc, Altomare, Daniele, Berthier, Marcelo, Bieler, Melanie, Brioschi, Andrea, Carrera, Emmanuel, Chételat, Gael, Csajka, Chantal, Demonet, Jean-François, Dodich, Alessandra, Dubois, Bruno, Garibotto, Valentina, Georges, Jean, Hurst, Samia, Kivipelto, Miia, J. Llewellyn, David, McWhirter, Laura, Milne, Richard, Minguillón, Carolina, Miniussi, Carlo, Nilsson, Peter M., Ritchie, Craig, Solomon, Alina, van der Flier, Wiesje, Vellas, Bruno, Visser, Leonie, Altomare, Daniele [0000-0003-1905-8993], and Apollo - University of Cambridge Repository
- Subjects
Gerontology ,medicine.medical_specialty ,Aging ,Risk profiling ,Cognitive Neuroscience ,Psychological intervention ,Neurosciences. Biological psychiatry. Neuropsychiatry ,Disease ,Review ,03 medical and health sciences ,0302 clinical medicine ,Alzheimer Disease ,Artificial Intelligence ,Brain health services ,medicine ,Dementia ,Humans ,RC346-429 ,030304 developmental biology ,Aged ,0303 health sciences ,Public health ,Framingham Risk Score ,business.industry ,Prevention ,Australia ,Brain ,Health Services ,Middle Aged ,medicine.disease ,3. Good health ,Alzheimer’s disease ,Risk factors ,Biomarkers ,Positron-Emission Tomography ,Risk Factors ,Neurology ,Neurology. Diseases of the nervous system ,Neurology (clinical) ,Alzheimer's disease ,Risk assessment ,business ,030217 neurology & neurosurgery ,Geriatric psychiatry ,RC321-571 - Abstract
We envisage the development of new Brain Health Services to achieve primary and secondary dementia prevention. These services will complement existing memory clinics by targeting cognitively unimpaired individuals, where the focus is on risk profiling and personalized risk reduction interventions rather than diagnosing and treating late-stage disease. In this article, we review key potentially modifiable risk factors and genetic risk factors and discuss assessment of risk factors as well as additional fluid and imaging biomarkers that may enhance risk profiling. We then outline multidomain measures and risk profiling and provide practical guidelines for Brain Health Services, with consideration of outstanding uncertainties and challenges. Users of Brain Health Services should undergo risk profiling tailored to their age, level of risk, and availability of local resources. Initial risk assessment should incorporate a multidomain risk profiling measure. For users aged 39–64, we recommend the Cardiovascular Risk Factors, Aging, and Incidence of Dementia (CAIDE) Dementia Risk Score, whereas for users aged 65 and older, we recommend the Brief Dementia Screening Indicator (BDSI) and the Australian National University Alzheimer’s Disease Risk Index (ANU-ADRI). The initial assessment should also include potentially modifiable risk factors including sociodemographic, lifestyle, and health factors. If resources allow, apolipoprotein E ɛ4 status testing and structural magnetic resonance imaging should be conducted. If this initial assessment indicates a low dementia risk, then low intensity interventions can be implemented. If the user has a high dementia risk, additional investigations should be considered if local resources allow. Common variant polygenic risk of late-onset AD can be tested in middle-aged or older adults. Rare variants should only be investigated in users with a family history of early-onset dementia in a first degree relative. Advanced imaging with 18-fluorodeoxyglucose positron emission tomography (FDG-PET) or amyloid PET may be informative in high risk users to clarify the nature and burden of their underlying pathologies. Cerebrospinal fluid biomarkers are not recommended for this setting, and blood-based biomarkers need further validation before clinical use. As new technologies become available, advances in artificial intelligence are likely to improve our ability to combine diverse data to further enhance risk profiling. Ultimately, Brain Health Services have the potential to reduce the future burden of dementia through risk profiling, risk communication, personalized risk reduction, and cognitive enhancement interventions.
- Published
- 2021
3. Dementia risk communication. A user manual for brain health Services-part 3 of 6
- Author
-
Visser Leonie N.C., Minguillón, Carolina, Sánchez Benavides, Gonzalo, Abramowicz, Marc, Altomare, Daniele, Fauria, Karine, Frisoni, Giovanni B., Georges, Jean, Ribaldi, Federica, Scheltens, Philip, Jetsk van der Schaar, Philip, Zwan, Marissa, van der Flier, Wiesje M., and Molinuevo, José Luis
- Subjects
Aging ,Prevention ,Brain Health Services ,Dementia ,Alzheimer’s disease ,Risk communication - Abstract
Growing evidence suggests dementia incidence can be reduced through prevention programs targeting risk factors. To accelerate the implementation of such prevention programs, a new generation of brain health services (BHS) is envisioned, involving risk profiling, risk communication, risk reduction, and cognitive enhancement. The purpose of risk communication is to enable individuals at risk to make informed decisions and take action to protect themselves and is thus a crucial step in tailored prevention strategies of the dementia incidence. However, communicating about dementia risk is complex and challenging.In this paper, we provide an overview of (i) perspectives on communicating dementia risk from an ethical, clinical, and societal viewpoint; (ii) insights gained from memory clinical practice; (iii) available evidence on the impact of disclosing APOE and Alzheimer's disease biomarker test results gathered from clinical trials and observational studies; (iv) the value of established registries in light of BHS; and (v) practical recommendations regarding effective strategies for communicating about dementia risk.In addition, we identify challenges, i.e., the current lack of evidence on what to tell on an individual level-the actual risk-and on how to optimally communicate about dementia risk, especially concerning worried yet cognitively unimpaired individuals. Ideally, dementia risk communication strategies should maximize the desired impact of risk information on individuals' understanding of their health/disease status and risk perception and minimize potential harms. More research is thus warranted on the impact of dementia risk communication, to (1) evaluate the merits of different approaches to risk communication on outcomes in the cognitive, affective and behavioral domains, (2) develop an evidence-based, harmonized dementia risk communication protocol, and (3) develop e-tools to support and promote adherence to this protocol in BHSs.Based on the research reviewed, we recommend that dementia risk communication should be precise; include the use of absolute risks, visual displays, and time frames; based on a process of shared decision-making; and address the inherent uncertainty that comes with any probability. This paper was the product of a workshop funded by the Swiss National Science Foundation entitled “Dementia Prevention Services” (grant number: IZSEZ0_193593). Additional funding was obtained from EURO-FINGERS, an EU Joint Programme - Neurodegenerative Disease Research (JPND) project. The EURO-FINGERS project is supported through the following funding organizations under the aegis of JPND - www.jpnd.eu: Finland, Academy of Finland; Germany, Federal Ministry of Education and Research; Spain, National Institute of Health Carlos III; Luxembourg, National Research Fund; Hungary, National Research, Development and Innovation Office; The Netherlands, Netherlands Organisation for Health Research and Development (ZonMW-Memorabel #733051102); Sweden, Swedish Research Council. LNCV is funded by an Alzheimer Nederland fellowship (WE.15-2019-05). The Barcelonaβeta Dementia Prevention Study and its registry have received funding from the Barcelona City Council (20190454), the Health Department of the Catalan Government, the Catalan Agency for Health Quality and Evaluation, and Biogen. Hersenonderzoek.nl is supported by ZonMw-Memorabel (#73305095003), Gieskes-Strijbis Foundation, Alzheimer Nederland and Hersenstichting. GBF received funding by the EU-EFPIA Innovative Medicines Initiatives 2 Joint Undertaking (IMI 2 JU) “European Prevention of Alzheimer’s Dementia consortium” (EPAD, grant agreement number: 115736) and “Amyloid Imaging to Prevent Alzheimer’s Disease” (AMYPAD, grant agreement number: 115952); the Swiss National Science Foundation: “Brain connectivity and metacognition in persons with subjective cognitive decline (COSCODE): correlation with clinical features and in vivo neuropathology” (grant number: 320030_182772). WF, LNCV, and PS are recipients of ABOARD, which is a public-private partnership receiving funding from ZonMW (#73305095007) and Health~Holland, Topsector Life Sciences & Health (PPP-allowance; #LSHM20106).
- Published
- 2021
4. Efficacy and safety of 12 versus 48 months of dual antiplatelet therapy after implantation of a drug-eluting stent: the OPTImal DUAL antiplatelet therapy (OPTIDUAL) trial: study protocol for a randomized controlled trial.
- Author
-
Helft, Gérard, Feuvre, Claude Le, Georges, Jean Louis, Carrie, Didier, Leclercq, Florence, Eltchaninoff, Hélène, Furber, Alain, Prunier, Fabrice, Sebagh, Laurent, Cattan, Simon, Cayla, Guillaume, Vicaut, Eric, and Metzger, Jean-Philippe
- Subjects
PLATELET aggregation inhibitors ,DRUG efficacy ,DRUG-eluting stents ,CLOPIDOGREL ,RANDOMIZED controlled trials ,CARDIOVASCULAR disease treatment ,THROMBOSIS - Abstract
Background: Dual antiplatelet therapy with aspirin and thienopyridine is required after placement of coronary drug-eluting stents (DES) to prevent thrombotic complications. Current clinical guidelines recommend at least 6 to 12 months of treatment after a DES implantation, but it may be beneficial to apply dual antiplatelet therapy for a longer duration. Methods/design: The optimal dual antiplatelet therapy (OPTIDUAL) study aims to compare the benefits and risks of dual antiplatelet therapy applied for either 12 or 48 months. We will examine the occurrence of major adverse cardiovascular and cerebrovascular events (MACCE) in patients undergoing percutaneous coronary intervention with DES for the treatment of coronary lesions. The OPTIDUAL study is an open-label multicenter, randomized, national trial that will include 1,966 patients treated with DES. All patients will be treated with dual antiplatelet therapy for 12 months (+/- 3). Then, patients with no MACCE or major bleeding will be randomized to receive either 36 additional months of clopidogrel plus aspirin or aspirin only. The primary end-point is the combination of death from all causes, myocardial infarction, stroke and major bleeding. The secondary end points include the individual components of the primary end-point, stent thrombosis, repeat revascularization of the treated vessel and minor bleeding. Discussion: This randomized trial is designed to assess the benefits and safety of 12 versus 48 months of dual antiplatelet therapy in patients that receive a DES. We aim to determine whether substantial prolongation of clopidogrel (a thienopyridine) after DES implantation offers an advantage over its discontinuation. [ABSTRACT FROM AUTHOR]
- Published
- 2013
- Full Text
- View/download PDF
5. Dementia risk communication. A user manual for brain health Services-part 3 of 6
- Author
-
Minguillón, Carolina, Visser Leonie N.C., Minguillón, Carolina, Sánchez Benavides, Gonzalo, Abramowicz, Marc, Altomare, Daniele, Fauria, Karine, Frisoni, Giovanni B., Georges, Jean, Ribaldi, Federica, Scheltens, Philip, Jetsk van der Schaar, Philip, Zwan, Marissa, van der Flier, Wiesje M., and Molinuevo, José Luis
- Published
- 2021
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.